Cure My Disease

Don't miss your cure!

 Log in / Sign up

Whey protein may tame blood sugar in prediabetes and diabetes

NCT ID NCT06694155

Symptom relief Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether drinking whey protein twice a day can improve blood sugar and insulin levels in people with prediabetes or type 2 diabetes. Researchers will measure blood sugar control and appetite in 40 adults aged 50-70 over two 7-day periods. The goal is to see if a simple dietary change can help manage blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and females ages 50-70 years. 2. Body mass index between 25-45 kg/m2 3. Capable of providing informed consent. 4. COVID-19 negative and/or asymptomatic. 5. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 7-day study meal period on two occasions. 6. HbA1c: 5.7-6.4% or 6.5% to 7.5% or fasting glucose ≥100 mg/dL Exclusion Criteria: 1. Subject who does not/will not eat dairy protein sources. 2. Subjects taking exogenous insulin injections or GLP /GIP injections or other appetite suppressants. 3. Unwilling to keep a detailed 7 day food journal on two occasions 4. Unwilling to wear a CGM for 7 days on two occasions and share the data with the research team. 5. Lactose intolerance. 6. Hemoglobin \<10g/dL at screening. 7. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment. 8. History of gastrointestinal bypass/reduction surgery. 9. Pregnant or lactating individuals. 10. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease) 11. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy. 12. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.). 13. Unwilling to avoid using protein or amino-acid supplements during participation. 14. Unwilling to fast overnight. 15. Any medical condition or medication that the PI or clinical study staff finds contradictory to this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes / type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes / type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Arkansas for Medical Sciences

    RECRUITING

    Little Rock, Arkansas, 72202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.